15 results on '"Renieri, Alessandra"'
Search Results
2. CAPRIN1 haploinsufficiency causes a neurodevelopmental disorder with language impairment, ADHD and ASD.
- Author
-
Pavinato, Lisa, Vedove, Andrea Delle, Carli, Diana, Ferrero, Marta, Carestiato, Silvia, Howe, Jennifer L, Agolini, Emanuele, Coviello, Domenico A, van de Laar, Ingrid, Au, Ping Yee Billie, Gregorio, Eleonora Di, Fabbiani, Alessandra, Croci, Susanna, Mencarelli, Maria Antonietta, Bruno, Lucia P, Renieri, Alessandra, Veltra, Danai, Sofocleous, Christalena, Faivre, Laurence, and Mazel, Benoit
- Subjects
LANGUAGE disorders ,ATTENTION-deficit hyperactivity disorder ,NEURAL development ,PLURIPOTENT stem cells ,NEURAL circuitry - Abstract
We describe an autosomal dominant disorder associated with loss-of-function variants in the Cell cycle associated protein 1 (CAPRIN1 ; MIM*601178). CAPRIN1 encodes a ubiquitous protein that regulates the transport and translation of neuronal mRNAs critical for synaptic plasticity, as well as mRNAs encoding proteins important for cell proliferation and migration in multiple cell types. We identified 12 cases with loss-of-function CAPRIN1 variants, and a neurodevelopmental phenotype characterized by language impairment/speech delay (100%), intellectual disability (83%), attention deficit hyperactivity disorder (82%) and autism spectrum disorder (67%). Affected individuals also had respiratory problems (50%), limb/skeletal anomalies (50%), developmental delay (42%) feeding difficulties (33%), seizures (33%) and ophthalmologic problems (33%). In patient-derived lymphoblasts and fibroblasts, we showed a monoallelic expression of the wild-type allele, and a reduction of the transcript and protein compatible with a half dose. To further study pathogenic mechanisms, we generated s CAPRIN1
+ / − human induced pluripotent stem cells via CRISPR–Cas9 mutagenesis and differentiated them into neuronal progenitor cells and cortical neurons. CAPRIN1 loss caused reduced neuronal processes, overall disruption of the neuronal organization and an increased neuronal degeneration. We also observed an alteration of mRNA translation in CAPRIN1+/− neurons, compatible with its suggested function as translational inhibitor. CAPRIN1+/− neurons also showed an impaired calcium signalling and increased oxidative stress, two mechanisms that may directly affect neuronal networks development, maintenance and function. According to what was previously observed in the mouse model, measurements of activity in CAPRIN1+/− neurons via micro-electrode arrays indicated lower spike rates and bursts, with an overall reduced activity. In conclusion, we demonstrate that CAPRIN1 haploinsufficiency causes a novel autosomal dominant neurodevelopmental disorder and identify morphological and functional alterations associated with this disorder in human neuronal models. [ABSTRACT FROM AUTHOR]- Published
- 2023
- Full Text
- View/download PDF
3. microRNA processor DROSHA is a candidate gene for a severe progressive neurological disorder.
- Author
-
Barish, Scott, Senturk, Mumine, Schoch, Kelly, Minogue, Amanda L, Lopergolo, Diego, Fallerini, Chiara, Harland, Jake, Seemann, Jacob H, Stong, Nicholas, Kranz, Peter G, Kansagra, Sujay, Mikati, Mohamad A, Jasien, Joan, El-Dairi, Mays, Galluzzi, Paolo, Network, Undiagnosed Diseases, Ariani, Francesca, Renieri, Alessandra, Mari, Francesca, and Wangler, Michael F
- Published
- 2022
- Full Text
- View/download PDF
4. The effect of angiotensin-converting enzyme levels on COVID-19 susceptibility and severity: a Mendelian randomization study.
- Author
-
Butler-Laporte, Guillaume, Nakanishi, Tomoko, Mooser, Vincent, Renieri, Alessandra, Amitrano, Sara, Zhou, Sirui, Chen, Yiheng, Forgetta, Vincenzo, and Richards, J Brent
- Subjects
COVID-19 ,COVID-19 pandemic ,ANGIOTENSIN converting enzyme ,COVID-19 treatment ,SARS-CoV-2 ,ACE inhibitors ,RESEARCH funding ,ICELANDERS - Abstract
Background: There has been uncertainty about the safety or benefit of angiotensin-converting enzyme (ACE) inhibitors during the COVID-19 pandemic. We used Mendelian randomization using genetic determinants of serum-ACE levels to test whether decreased ACE levels increase susceptibility to SARS-CoV-2 infection or COVID-19 severity, while reducing potential bias from confounding and reverse causation in observational studies.Methods: Genetic variants strongly associated with ACE levels, which were nearby the ACE gene, were identified from the ORIGIN trial and a separate genome-wide association study (GWAS) of ACE levels from the AGES cohort. The ORIGIN trial included 4147 individuals of European and Latino ancestries. Sensitivity analyses were performed using a study of 3200 Icelanders. Cohorts from the COVID-19 Host Genetics Initiative GWAS of up to 960 186 individuals of European ancestry were used for COVID-19 susceptibility, hospitalization and severe-disease outcome.Results: Genetic variants were identified that explain between 18% and 37% of variance in ACE levels. Using genetic variants from the ORIGIN trial, a standard-deviation decrease in ACE levels was not associated with an increase in COVID-19 susceptibility [odds ratio (OR): 1.02, 95% confidence interval (CI): 0.90, 1.15], hospitalization (OR: 0.86, 95% CI: 0.68, 1.08) or severe disease (OR: 0.74, 95% CI: 0.51, 1.06). Using genetic variants from the AGES cohort, the result was similar for susceptibility (OR: 0.98, 95% CI: 0.89, 1.09), hospitalization (OR: 0.86, 95% CI: 0.66, 1.11) and severity (OR: 0.75, 95% CI: 0.50, 1.14). Multiple-sensitivity analyses led to similar results.Conclusion: Genetically decreased serum ACE levels were not associated with susceptibility to, or severity of, COVID-19 disease. These data suggest that individuals taking ACE inhibitors should not discontinue therapy during the COVID-19 pandemic. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
5. Variants in the SK2 channel gene (KCNN2) lead to dominant neurodevelopmental movement disorders.
- Author
-
Mochel, Fanny, Rastetter, Agnès, Ceulemans, Berten, Platzer, Konrad, Yang, Sandra, Shinde, Deepali N, Helbig, Katherine L, Lopergolo, Diego, Mari, Francesca, Renieri, Alessandra, Benetti, Elisa, Canitano, Roberto, Waisfisz, Quinten, Plomp, Astrid S, Huisman, Sylvia A, Wilson, Golder N, Cathey, Sara S, Louie, Raymond J, Gaudio, Daniela Del, and Waggoner, Darrel
- Subjects
CALCIUM-dependent potassium channels ,CEREBELLAR ataxia ,MOVEMENT disorders ,GAIT disorders ,FRAMESHIFT mutation ,LEARNING disabilities ,RECESSIVE genes ,BRAIN abnormalities ,BRAIN ,GENETIC mutation ,GENETICS ,MAGNETIC resonance imaging ,ELECTROPHYSIOLOGY ,GENOMES ,CYTOLOGY - Abstract
KCNN2 encodes the small conductance calcium-activated potassium channel 2 (SK2). Rodent models with spontaneous Kcnn2 mutations show abnormal gait and locomotor activity, tremor and memory deficits, but human disorders related to KCNN2 variants are largely unknown. Using exome sequencing, we identified a de novo KCNN2 frameshift deletion in a patient with learning disabilities, cerebellar ataxia and white matter abnormalities on brain MRI. This discovery prompted us to collect data from nine additional patients with de novo KCNN2 variants (one nonsense, one splice site, six missense variants and one in-frame deletion) and one family with a missense variant inherited from the affected mother. We investigated the functional impact of six selected variants on SK2 channel function using the patch-clamp technique. All variants tested but one, which was reclassified to uncertain significance, led to a loss-of-function of SK2 channels. Patients with KCNN2 variants had motor and language developmental delay, intellectual disability often associated with early-onset movement disorders comprising cerebellar ataxia and/or extrapyramidal symptoms. Altogether, our findings provide evidence that heterozygous variants, likely causing a haploinsufficiency of the KCNN2 gene, lead to novel autosomal dominant neurodevelopmental movement disorders mirroring phenotypes previously described in rodents. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
6. SLC12A2 variants cause a neurodevelopmental disorder or cochleovestibular defect.
- Author
-
McNeill, Alisdair, Iovino, Emanuela, Mansard, Luke, Vache, Christel, Baux, David, Bedoukian, Emma, Cox, Helen, Dean, John, Goudie, David, Kumar, Ajith, Newbury-Ecob, Ruth, Fallerini, Chiara, Renieri, Alessandra, Lopergolo, Diego, Mari, Francesca, Blanchet, Catherine, Willems, Marjolaine, Roux, Anne-Francoise, Pippucci, Tommaso, and Delpire, Eric
- Subjects
HEARING disorders ,XENOPUS laevis ,NEUROGLIA ,CELL analysis ,DEVELOPMENTAL delay ,VESTIBULAR apparatus diseases - Abstract
The SLC12 gene family consists of SLC12A1-SLC12A9, encoding electroneutral cation-coupled chloride co-transporters. SCL12A2 has been shown to play a role in corticogenesis and therefore represents a strong candidate neurodevelopmental disorder gene. Through trio exome sequencing we identified de novo mutations in SLC12A2 in six children with neurodevelopmental disorders. All had developmental delay or intellectual disability ranging from mild to severe. Two had sensorineural deafness. We also identified SLC12A2 variants in three individuals with non-syndromic bilateral sensorineural hearing loss and vestibular areflexia. The SLC12A2 de novo mutation rate was demonstrated to be significantly elevated in the deciphering developmental disorders cohort. All tested variants were shown to reduce co-transporter function in Xenopus laevis oocytes. Analysis of SLC12A2 expression in foetal brain at 16-18 weeks post-conception revealed high expression in radial glial cells, compatible with a role in neurogenesis. Gene co-expression analysis in cells robustly expressing SLC12A2 at 16-18 weeks post-conception identified a transcriptomic programme associated with active neurogenesis. We identify SLC12A2 de novo mutations as the cause of a novel neurodevelopmental disorder and bilateral non-syndromic sensorineural hearing loss and provide further data supporting a role for this gene in human neurodevelopment. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
7. Gene replacement ameliorates deficits in mouse and human models of cyclin-dependent kinase-like 5 disorder.
- Author
-
Gao, Yunan, Irvine, Elaine E, Eleftheriadou, Ioanna, Naranjo, Carlos Jiménez, Hearn-Yeates, Francesca, Bosch, Leontien, Glegola, Justyna A, Murdoch, Leah, Czerniak, Aleksandra, Meloni, Ilaria, Renieri, Alessandra, Kinali, Maria, and Mazarakis, Nicholas D
- Subjects
POSTSYNAPTIC density protein ,PURKINJE cells ,TRANSGENE expression ,NEUROGLIA ,SLOW wave sleep ,KNOCKOUT mice ,APOLIPOPROTEIN E4 ,BRAIN metabolism ,CALCIUM metabolism ,PROTEINS ,RESEARCH ,NEURONS ,CELL culture ,VIRUSES ,ANIMAL experimentation ,NERVOUS system ,RESEARCH methodology ,EVALUATION research ,MEDICAL cooperation ,COMPARATIVE studies ,TRANSFERASES ,GENE therapy ,STEM cells ,GENETIC techniques ,MICE - Abstract
Cyclin-dependent kinase-like 5 disorder is a severe neurodevelopmental disorder caused by mutations in the X-linked cyclin-dependent kinase-like 5 (CDKL5) gene. It predominantly affects females who typically present with severe early epileptic encephalopathy, global developmental delay, motor dysfunction, autistic features and sleep disturbances. To develop a gene replacement therapy, we initially characterized the human CDKL5 transcript isoforms expressed in the brain, neuroblastoma cell lines, primary astrocytes and embryonic stem cell-derived cortical interneurons. We found that the isoform 1 and to a lesser extent the isoform 2 were expressed in human brain, and both neuronal and glial cell types. These isoforms were subsequently cloned into recombinant adeno-associated viral (AAV) vector genome and high-titre viral vectors were produced. Intrajugular delivery of green fluorescence protein via AAV vector serotype PHP.B in adult wild-type male mice transduced neurons and astrocytes throughout the brain more efficiently than serotype 9. Cdkl5 knockout male mice treated with isoform 1 via intrajugular injection at age 28-30 days exhibited significant behavioural improvements compared to green fluorescence protein-treated controls (1012 vg per animal, n = 10 per group) with PHP.B vectors. Brain expression of the isoform 1 transgene was more abundant in hindbrain than forebrain and midbrain. Transgene brain expression was sporadic at the cellular level and most prominent in hippocampal neurons and cerebellar Purkinje cells. Correction of postsynaptic density protein 95 cerebellar misexpression, a major fine cerebellar structural abnormality in Cdkl5 knockout mice, was found in regions of high transgene expression within the cerebellum. AAV vector serotype DJ efficiently transduced CDKL5-mutant human induced pluripotent stem cell-derived neural progenitors, which were subsequently differentiated into mature neurons. When treating CDKL5-mutant neurons, isoform 1 expression led to an increased density of synaptic puncta, while isoform 2 ameliorated the calcium signalling defect compared to green fluorescence protein control, implying distinct functions of these isoforms in neurons. This study provides the first evidence that gene therapy mediated by AAV vectors can be used for treating CDKL5 disorder. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
8. Advances and unmet needs in genetic, basic and clinical science in Alport syndrome: report from the 2015 International Workshop on Alport Syndrome.
- Author
-
Gross, Oliver, Kashtan, Clifford E., Rheault, Michelle N., Flinter, Frances, Savige, Judith, Miner, Jeffrey H., Torra, Roser, Ars, Elisabet, Deltas, Constantinos, Savva, Isavella, Perin, Laura, Renieri, Alessandra, Ariani, Francesca, Mari, Francesca, Baigent, Colin, Judge, Parminder, Knebelman, Bertrand, Heidet, Laurence, Lagas, Sharon, and Blatt, Dave
- Subjects
ALPORT syndrome ,COLLAGEN ,ANGIOTENSIN converting enzyme ,KIDNEY failure ,GENETICS - Abstract
Alport syndrome (AS) is a genetic disease characterized by haematuric glomerulopathy variably associated with hearing loss and anterior lenticonus. It is caused by mutations in the COL4A3, COL4A4 or COL4A5 genes encoding the α3α4α5(IV) collagen heterotrimer. AS is rare, but it accounts for >1% of patients receiving renal replacement therapy. Angiotensin-converting enzyme inhibition slows, but does not stop, the progression to renal failure; therefore, there is an urgent requirement to expand and intensify research towards discovering new therapeutic targets and new therapies. The 2015 International Workshop on Alport Syndrome targeted unmet needs in basic science, genetics and diagnosis, clinical research and current clinical care. In three intensive days, more than 100 international experts including physicians, geneticists, researchers from academia and industry, and patient representatives from all over the world participated in panel discussions and breakout groups. This report summarizes the most important priority areas including (i) understanding the crucial role of podocyte protection and regeneration, (ii) targeting mutations by new molecular techniques for new animal models and potential gene therapy, (iii) creating optimal interaction between nephrologists and geneticists for early diagnosis, (iv) establishing standards for mutation screening and databases, (v) improving widespread accessibility to current standards of clinical care, (vi) improving collaboration with the pharmaceutical/biotech industry to investigate new therapies, (vii) research in hearing loss as a huge unmet need in Alport patients and (viii) the need to evaluate the risk and benefit of novel (including ‘repurposing’) therapies on an international basis. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
9. Clonality Analysis of Immunoglobulin Gene Rearrangement by Next-Generation Sequencing in Endemic Burkitt Lymphoma Suggests Antigen Drive Activation of BCR as Opposed to Sporadic Burkitt Lymphoma.
- Author
-
Amato, Teresa, Abate, Francesco, Piccaluga, Pierpaolo, Iacono, Michele, Fallerini, Chiara, Renieri, Alessandra, De Falco, Giulia, Ambrosio, Maria Raffaella, Mourmouras, Vaselious, Ogwang, Martin, Calbi, Valeria, Rabadan, Roul, Hummel, Michael, Pileri, Stefano, Leoncini, Lorenzo, and Bellan, Cristiana
- Subjects
BURKITT'S lymphoma ,TRANSCRIPTION factors ,HELIX-loop-helix motifs ,GENETIC mutation ,RNA sequencing ,B cell receptors ,IMMUNOGLOBULINS ,B cell lymphoma ,GENES ,PROTEINS ,SEQUENCE analysis - Abstract
Objectives: Recent studies using next-generation sequencing (NGS) analysis disclosed the importance of the intrinsic activation of the B-cell receptor (BCR) pathway in the pathogenesis of sporadic Burkitt lymphoma (sBL) due to mutations of TCF3/ID3 genes. Since no definitive data are available on the genetic landscape of endemic Burkitt (eBL), we first assessed the mutation frequency of TCF3/ID3 in eBL compared with sBL and subsequently the somatic hypermutation status of the BCR to answer whether an extrinsic activation of BCR signaling could also be demonstrated in Burkitt lymphoma.Methods: We assessed the mutations of TCF3/ID3 by RNAseq and the BCR status by NGS analysis of the immunoglobulin genes (IGs).Results: We detected mutations of TCF3/ID3 in about 30% of the eBL cases. This rate is significantly lower than that detected in sBL (64%). The NGS analysis of IGs revealed intraclonal diversity, suggesting an active targeted somatic hypermutation process in eBL compared with sBL.Conclusions: These findings support the view that the antigenic pressure plays a key role in the pathogenetic pathways of eBL, which may be partially distinct from those driving sBL development. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
10. The role of surgical lung biopsy in the management of interstitial lung disease: experience from a single institution in the UK.
- Author
-
Blackhall, Vivienne, Asif, Mohammed, Renieri, Alessandra, Civitelli, Serenella, Kirk, Alan, Jilaihawi, Ali, and Granato, Felice
- Published
- 2013
- Full Text
- View/download PDF
11. CDKL5 belongs to the same molecular pathway of MeCP2 and it is responsible for the early-onset seizure variant of Rett syndrome.
- Author
-
Mari, Francesca, Azimonti, Sara, Bertani, Ilaria, Bolognese, Fabrizio, Colombo, Elena, Caselli, Rossella, Scala, Elisa, Longo, Ilaria, Grosso, Salvatore, Pescucci, Chiara, Ariani, Francesca, Hayek, Giuseppe, Balestri, Paolo, Bergo, Anna, Badaracco, Gianfranco, Zappella, Michele, Broccoli, Vania, Renieri, Alessandra, Kilstrup-Nielsen, Charlotte, and Landsberger, Nicoletta
- Published
- 2005
- Full Text
- View/download PDF
12. Analysis of the OA1 gene reveals mutations in only one-third of patients with X-linked ocular albinism.
- Author
-
Schiaffino, M.Vittoria, Bassi, Maria T., Galli, Lucia, Renieri, Alessandra, Bruttini, Mirella, Nigris, Filomena De, Bergen, Arthur A.B., Charles, Stephen J., Yates, John R.W., Meindl, Alfons, Lewis, Richard A., King, Richard A., and Ballabio, Andrea
- Published
- 1995
13. Cloning of a human homologue of the Xenopus Iaevis APX gene from the ocular albinism type 1 critical region.
- Author
-
Schiaffino, M.Vittoria, Bassi, Maria T., Rugarli, Elena I., Renieri, Alessandra, Galli, Lucia, and Ballabio, Andrea
- Published
- 1995
14. De novo mutation in the COL4A5 gene converting glycine 325 to glutamic acid in Alport syndrome.
- Author
-
Renieri, Alessandra, Seri, Marco, Myers, Jeanne C., pihlajaniemi, Taina, Massella, Laura, Rizzoni, Gianfranco, and Marchi, Mario De
- Published
- 1992
15. Single base pair deletions in exons 39 and 42 of the COL4A5 gene in Alport syndrome.
- Author
-
Renieri, Alessandra, Galli, Lucia, De Marchl, Mario, Mollica, Florindo, Lupo, Antonio, Maschio, Giuseppe, Peissel, Bernard, Rossetti, Sandro, Pignatti, Pierfranco, and E.Turco, Alberto
- Published
- 1994
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.